Artificial Intelligence
April 23–25, 2018
Boston, MA • United States

Past Forum: 2017 (London)

Summary

Where High-Impact Global Initiatives Begin

The World Neuroscience Innovation Forum was a tailored, neuroscience gathering that built on the broad success of the flagship Annual Forums. The Neuroscience Forum took place in London at the Francis Crick Institute on 27 March 2017. It featured highly-interactive exchanges among neuroscience leaders, with the aim of turning insights into action. The Forum was being jointly hosted by Partners HealthCare and the Francis Crick Institute. It was a collaboration among them, leading pharmaceutical and biotechnology companies, investors and other academic centers. The goal of the Forum is to spark new insights, therapeutic paths and collaborations to combat neuroinflammation and neurodegeneration. The Forum convened international leaders from throughout the neuroscience community, including principals from the corporate, academic, government, foundation and investment sectors.

The objectives:

  • Launch focused translation and commercialization collaborations to address unmet needs.
  • Seed new and grow world-class international neuroscience teams that will lead to high impact commercial products.
  • Initiate Springboard Challenge designed to position new international commercialization-oriented teams for substantial industry, government and philanthropic support.
  • Increase interactions among top neuro-oriented investigators, investors, entrepreneurs, corporate leaders, philanthropists and government executives across Europe and in the US.

Keynoters

David Mayhew, CBE

UK Dementia Envoy; Chairman, Alzheimer's Research UK

Michael Ehlers, MD, PhD

EVP, Head of R&D, Biogen

John Lechleiter, PhD

Chairman, Eli Lilly and Company

Alfred Sandrock, MD, PhD

EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen

Reisa Sperling, MD

Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital; Professor of Neurology, Harvard Medical School

Hilary Evans

CEO, Alzheimer's Research UK

Kate Bingham

Managing Partner, SVLS

Bob Oliver

CEO, Otsuka America Pharmaceutical

Husseini Manji, MD

Global Therapeutic Head, Neuroscience, Janssen R&D

Michael Hutton, PhD

CSO, Neuroscience, Eli Lilly and Company

Merit Cudkowicz, MD

Chair of Neurology, Massachusetts General Hospital; Julianne Dorn Professor of Neurology, Harvard Medical School

Min Li, PhD

SVP, Global Head of Neurosciences, GlaxoSmithKline

John Lepore, MD

SVP, R&D Pipeline, GlaxoSmithKline

Rudolph Tanzi, PhD

Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School

Ole Isacson, MD, PhD

Principal Investigator Harvard Stem Cell Institute, McLean Hospital; Professor of Neurology and Neuroscience, Harvard Medical School

Michael Hayden, MD, PhD

President of Global R&D, CSO, Teva Pharmaceutical Industries

Richard Rudick, MD

VP Development Sciences, Biogen

Steven Paul, MD

CEO, Voyager Therapeutics

Jean-François Formela, MD

Partner, Atlas Venture

David Roblin, MD

COO and Director of Scientific Translation, The Francis Crick Institute

Hugh Perry, PhD

Professor of Experimental Neuropathology, University of Southampton

Gillian Leng, MD

Deputy Chief Executive, National Institute for Health and Care Excellence

Anne Klibanski, MD

Chief Academic Officer, Partners HealthCare; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School

Brad Hyman, MD, PhD

Director, MGH Alzheimer's Disease Research Center, Massachusetts General Hospital; John B. Penny, Jr. Professor Neurology, Harvard Medical School

Martin Samuels, MD

Chair, Department of Neurology, Brigham and Women's Hospital; Miriam Sydney Joseph Professor of Neurology, Harvard Medicine School

Dennis Selkoe, MD

Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Vincent and Stellla Coates Professor of Neurologic Diseases, Harvard Medical School

Howard Weiner, MD

Director, Multiple Sclerosis Program, Brigham and Women's Hospital; Robert L. Kroc Professor of Neurology, Harvard Medical School

Panels

Monday, March 27, 2017

Disease Modifying Therapies: Getting over the Technology Threshold

  • Jean-François Formela, MD
    Partner, Atlas Venture
  • Kate Bingham
    Managing Partner, SVLS
  • Min Li, PhD
    SVP, Global Head of Neurosciences, GlaxoSmithKline
  • Vivek Ramaswamy
    CEO, Roivant Sciences
  • Alfred Sandrock, MD, PhD
    EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen
  • Dennis Selkoe, MD
    Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School

Expanding the Diagnostic Spectrum: Tools, Technologies, and Tracers

  • Bruce Rosen, MD, PhD
    Director, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
  • Roger Gunn, PhD
    CSO, Imanova; Professor of Molecular Neuroimaging, Department of Medicine, Imperial College, London
  • Jacob Hooker, PhD
    Phyllis and Jerome Lyle Rappaport MGH Research Scholar, Director of Radiochemistry, Athinoula A. Martinos Center, Massachusetts General Hospital; Associate Professor in Radiology, Harvard Medical School
  • Robert Krieg, PhD
    VP of MR Product Definition & Innovation, Siemens
  • Eddie Martucci, PhD
    CEO, Akili Interactive Labs
  • Henrik Zetterberg, MD, PhD
    Professor of Neurochemistry, Head of Lab, UCL; Professor of Neurochemistry, Head of Department, University of Gothenburg

1:1 Fireside Chat - John Lechleiter

  • Hilary Evans
    CEO, Alzheimer’s Research UK
  • John Lechleiter, PhD
    Chairman, Eli Lilly and Company

Patient Interview

  • Martin Samuels, MD
    Chair, Department of Neurology, Brigham and Women’s Hospital; Miriam Sydney Joseph Professor of Neurology, Harvard Medical School
  • Brenda and Stephen Whittle, PhD
    Dementia Patient & Caregiver, Dementia Advocates and Volunteer Partners with ARUK (Alzheimer’s Research UK)

Neurodegeneration and Neuroinflammation: A Grand Unifying Theory for Drug Development?

  • Rudolph Tanzi, PhD
    Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
  • Christian Haass, PhD
    Institute Head, German Center for Neurodegenerative Disease
  • Michael Hayden, MD, PhD
    President of Global R&D, CSO, Teva Pharmaceutical Industries
  • Michael Hutton, PhD
    CSO, Neuroscience, Eli Lilly and Company
  • Roger Nitsch, MD
    President, Neurimmune Holding AG
  • Hugh Perry, PhD
    Professor of Experimental Neuropathology, University of Southampton

Lunch Breakout: Depression and Neuroinflammation

  • Philip Iredale, PhD
    VP Head of Circuits, Neuro-Opportunities & Screening, Technologies, Pfizer
  • Declan Jones, PhD
    VP, Neuroscience Lead, J&J London Innovation Centre, Johnson & Johnson
  • Kerry Ressler, MD, PhD
    CSO, McLean Hospital; Professor in Psychiatry, Harvard Medical School

The Promise and Current Role of Gene and Cell Therapy

  • Ole Isacson, MD, PhD
    Principal Investigator Harvard Stem Cell Institute, McLean Hospital; Professor of Neurology and Neuroscience, Harvard Medical School
  • Timothy Cox, MD
    Professor of Medicine Emeritus, Director of Research, Honorary Consultant Physician, University of Cambridge
  • Brad Hyman, MD, PhD
    Director, Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital; John B. Penney Professor of Neurology, Harvard Medical School
  • Gillian Leng, MD
    Deputy Chief Executive, National Institute for Health and Care Excellence
  • Steven Paul, MD
    CEO, Voyager Therapeutics

Next-Generation Therapies and Diagnostics: Big Data and Digital Health

  • Shawn Murphy, MD, PhD
    Corporate Director of Research Information Systems and Computing, Partners HealthCare; Associate Professor of Neurology, Harvard Medical School
  • Jenny Barnett, PhD
    CSO, Cambridge Cognition
  • John Gallacher, PhD
    Director, MRC Dementias Platform UK
  • Husseini Manji, MD
    Global Therapeutic Area Head, Neuroscience, Janssen R&D
  • Richard Rudick, MD
    VP Development Sciences, Biogen
  • Howard Weiner, MD
    Director, Multiple Sclerosis Program, Brigham and Women's Hospital; Robert L. Kroc Professor of Neurology, Harvard Medical School

1:1 Fireside - Alfred Sandrock

  • Rudolph Tanzi, PhD
    Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
  • Alfred Sandrock, MD, PhD
    EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen

Implementing Novel Models in Alzheimer’s Trials: How Can We Transform the Cost-Benefit Equation for Trials?

  • Reisa Sperling, MD
    Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital; Professor of Neurology, Harvard Medical School
  • Iain Chessell, PhD
    VP Neuroscience IMED MedImmune, AstraZeneca
  • Michael Krams, MD
    Global Head of Quantitative Sciences, Janssen Pharmaceuticals
  • Craig Ritchie, MD, PhD
    Professor of Psychiatry of Ageing University of Edinburgh
  • Nadeem Sarwar, MD, PhD
    President, AiM Institute, Eisai

The Crisis We Want: Are Healthcare Systems Prepared for a Disease-Modifying Drug?

  • Merit Cudkowicz, MD
    Chair, Department of Neurology, Massachusetts General Hospital; Julieanne Dorn Professor of Neurology, Harvard Medical School
  • Phyllis Ferrell
    VP, Global Alzheimer’s Disease Platform Team, Eli Lilly and Company
  • Tim Ferris, MD
    Senior Vice President of Population HealthCare Management, Partners HealthCare; Associate Professor of Medicine and Pediatrics, Harvard Medical School
  • Geoff Huggins
    Director of Health Social Care and Integration, Scottish Government
  • Bob Oliver
    CEO, Otsuka America Pharmaceutical

Announcement and Discussion of the Springboard Challenge

  • Christopher Coburn
    Chief Innovation Officer, Partners HealthCare
  • John Lepore, MD
    SVP, R&D Pipeline GlaxoSmithKline